BNP Paribas Arbitrage SA Increases Stake in Qiagen N.V. (QGEN)
BNP Paribas Arbitrage SA lifted its holdings in shares of Qiagen N.V. (NASDAQ:QGEN) by 8.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,763 shares of the company’s stock after acquiring an additional 1,742 shares during the period. BNP Paribas Arbitrage SA’s holdings in Qiagen N.V. were worth $730,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in QGEN. Capital Fund Management S.A. purchased a new position in shares of Qiagen N.V. during the first quarter worth approximately $768,000. Bank of New York Mellon Corp grew its position in shares of Qiagen N.V. by 13.7% during the first quarter. Bank of New York Mellon Corp now owns 1,222,959 shares of the company’s stock worth $35,430,000 after acquiring an additional 147,752 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in shares of Qiagen N.V. by 4.1% during the first quarter. Parametric Portfolio Associates LLC now owns 651,832 shares of the company’s stock worth $18,884,000 after acquiring an additional 25,582 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in shares of Qiagen N.V. during the first quarter worth approximately $667,000. Finally, M&T Bank Corp purchased a new position in shares of Qiagen N.V. during the first quarter worth approximately $230,000. Institutional investors and hedge funds own 63.01% of the company’s stock.
A number of brokerages have recently issued reports on QGEN. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research report on Friday, June 23rd. TheStreet upgraded shares of Qiagen N.V. from a “c” rating to a “b” rating in a research report on Monday, June 5th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Monday, July 24th. Bank of America Corporation reaffirmed a “neutral” rating and set a $36.00 price target (up from $33.00) on shares of Qiagen N.V. in a report on Friday, July 21st. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $37.00 price target (up from $33.00) on shares of Qiagen N.V. in a report on Monday, July 17th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $33.17.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/11/bnp-paribas-arbitrage-sa-increases-stake-in-qiagen-n-v-qgen.html.
Shares of Qiagen N.V. (NASDAQ:QGEN) opened at 32.00 on Monday. Qiagen N.V. has a 12-month low of $24.86 and a 12-month high of $35.26. The firm has a market cap of $7.30 billion, a P/E ratio of 97.86 and a beta of 1.15. The firm has a 50-day moving average price of $32.24 and a 200-day moving average price of $31.54.
Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The firm had revenue of $349 million during the quarter, compared to the consensus estimate of $353.09 million. During the same period in the prior year, the business earned $0.24 EPS. The firm’s revenue was up 4.4% on a year-over-year basis. On average, equities research analysts expect that Qiagen N.V. will post $1.20 earnings per share for the current fiscal year.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.